Trial Profile
The effects of nateglinide and acarbose on the post-prandial glucose control in type 2 diabetic patients
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 10 Nov 2021
Price :
$35
*
At a glance
- Drugs Nateglinide (Primary) ; Acarbose
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- 21 Mar 2008 Status changed from recruiting to completed, as reported by ClinicalTrials.gov.
- 26 Mar 2007 New trial record.